Management Is Clueless

Quote
anonymous said:
Where do you get these ideas?
aCGRP will grow in PCP to eventually overtake Neuro. Established Specialty reps will carry that as well as our heightened role in PM. We will launch Fas in PCP and PM. Maybe combine salesforces but not eliminate. We are spread thin compared to comp as it is
Just my opinion
Click to expand...


Nice opinion, but Teva is moving into biologics and this is the only way to filter out all those primary care respiratory sample pushers. Gen-Pharma is done. If you're not moving into the specialty/biosimilar talent and pay scale level, you will be left behind.
 






Respiratory sample pushers?
Nice coming from the Neuro Account Maintenance Crew.
How long has it been since you actually sold something? Unless you were in early you were just riding that drug out - 10 to 2 everyday, lunch and done.
If you are such a superior biologic sales force and all the Ajovy volume is coming thru Neuro - why is Ajovy coming in a distant third place?
 






anonymous said:
Respiratory sample pushers?
Nice coming from the Neuro Account Maintenance Crew.
How long has it been since you actually sold something? Unless you were in early you were just riding that drug out - 10 to 2 everyday, lunch and done.
If you are such a superior biologic sales force and all the Ajovy volume is coming thru Neuro - why is Ajovy coming in a distant third place?
Click to expand...

It’s called terrible formulary coverage and no autoject until now. It still begs the question numb nuts, why do PCP reps account for only 5-10% of all Ajovy scripts?
 






Those sound like excuses for someone of your pay and talent level?
Of the volume is less in PCP, they see less migraine patients and many if not most refer. That will change as their comfort level grows with use.
Neuro will only see the most difficult patients as the class matures
 






We have very little to do. Also, dumb asses being non compliant so now we have even mess to do. I’m concerned we will not be able to do nothing and get paid much longer.
 






anonymous said:
Those sound like excuses for someone of your pay and talent level?
Of the volume is less in PCP, they see less migraine patients and many if not most refer. That will change as their comfort level grows with use.
Neuro will only see the most difficult patients as the class matures
Click to expand...

So, if you have three products that are similar and one has terrible formulary access and is harder to administer, you think anything other than third is doable? The fact is, the PCP reps aren’t pulling their weight. People keep saying all the business is going to be with the PCP offices. When will this drastic shift happen? You’re an idiot.
 






And you're a self inflated tool
FYI Specialty to Neuro is a lateral move - no pay increase
And you are not making anywhere near what a 'biologic' salesforce is, none of us are.
Besides all that, I'm just glad we all still have jobs
Go One Teva!
 






anonymous said:
So, if you have three products that are similar and one has terrible formulary access and is harder to administer, you think anything other than third is doable? The fact is, the PCP reps aren’t pulling their weight. People keep saying all the business is going to be with the PCP offices. When will this drastic shift happen? You’re an idiot.
Click to expand...

You just answered your question - Specialty is in the same boat - weak NC, formerly antiquated device with much less volume = less contribution. It may be longer than you expect but it will shift, hopefully they will combine salesforces.
 




































anonymous said:
As always it depends on the local leadership you are dealing with. Some do not care if you get kicked out of offices for the constant phone calls and requests for virtual details to doctors, while they are dealing with changes and stress in their own practices and personal lives. I think pharmaceuticals will look very different after this because companies in the industry are harassing the physicians in the name of helping them. Our customers see it for what it is.
Click to expand...

The numbers are not bearing out the use of the virtual engage details. People that are doing them are not increasing their numbers anymore than others. Some numbers are dropping.
 






It came straight from the national Sales Performance Summary. Emailed out each week.
How about some more fun facts! Over the past 12 months, there are only 9,627 total targets writing.
2,404 scripts came from the targets Specialty division calls on and 7,226 from Neuro division.
That breaks down to 25% Specialty and 75% Neuro division. This is a very proportionate ratio between the 2 sales forces when you consider the concentration of migraine patients seen by a neuro vs primary care.
TN sales force certainly produces the bulk of the TRXs, but the Specialty team is out cultivating new prescribers. The more collaboration between the divisions, positive results occur!
 


















anonymous said:
It came straight from the national Sales Performance Summary. Emailed out each week.
How about some more fun facts! Over the past 12 months, there are only 9,627 total targets writing.
2,404 scripts came from the targets Specialty division calls on and 7,226 from Neuro division.
That breaks down to 25% Specialty and 75% Neuro division. This is a very proportionate ratio between the 2 sales forces when you consider the concentration of migraine patients seen by a neuro vs primary care.
TN sales force certainly produces the bulk of the TRXs, but the Specialty team is out cultivating new prescribers. The more collaboration between the divisions, positive results occur!
Click to expand...
Thank you management. This message is so clearly written by someone in home office. The fact is many headache specialists are non-Neurologists which account for a ton of scripts. Take them out of the equation and Specialty is back down to 5%
 


















Top Bottom
Back
Quote